January 8, 2020

Italfarmaco Shares Winter 2020 Newsletter

Italfarmaco has shared the Winter 2020 issue of their newsletter, including updates on the Givinostat Development Program. Click here to download.

Learn More

January 8, 2020

Catabasis Shares January 2020 Newsletter

Catabasis shares the latest edition of their community newsletter, including information about the Phase 3 PolarisDMD trial enrolling the expected patient population and a partnership with our friends at Duchenne UK to evaluate edasalonexent in…

Learn More

January 7, 2020

PPMD’s Endurance Program – Race to End Duchenne – Celebrates 15 Years of Going the Distance to End Duchenne

Parent Project Muscular Dystrophy (PPMD) celebrates the 15th anniversary of our endurance fundraising program, Race to End Duchenne, this weekend in Orlando. Over 170 team members will participate in the 2020 WALT DISNEY WORLD® MARATHON…

Learn More

January 3, 2020

Thank you for making today better!

We can’t begin to express our gratitude to everyone who donated to PPMD this holiday season! Thanks to your generosity, and a community match, I am thrilled to announce that we reached our ambitious fundraising…

Learn More

December 27, 2019

Donate to PPMD today and help make tomorrow TWICE as strong

I know we are right in the thick of the holiday season with a new year quickly approaching, so I thank you for taking a minute to read this note. The holidays can be a…

Learn More

December 23, 2019

Advocacy Matters! Duchenne Community Requests Included in 2020 Federal Budget

Bipartisan agreement reached on funding bill includes Duchenne specific funding levels and report language advocated for by PPMD advocates! Who says Congress can’t agree on anything? After 147 in-person meetings in Washington DC by Duchenne…

Learn More

December 23, 2019

Sarepta Announces Partnership with Roche Outside the U.S. for its Investigational Micro-dystrophin Gene Therapy

Sarepta Therapeutics, Inc. today announced that Sarepta and Roche have entered into a licensing agreement providing Roche exclusive commercial rights to SRP-9001 (AAVrh74.MHCK7.micro-dystrophin), Sarepta’s investigational gene therapy for Duchenne muscular dystrophy, outside the United States….

Learn More

December 20, 2019

Sarepta Therapeutics Shares Winter 2019 Newsletter

Sarepta has shared the Winter 2019 issue of their newsletter, including updates on current Sarepta programs. Click here to download.

Learn More

December 20, 2019

WATCH: Better Todays. Stronger Tomorrows. – Webinar Recording

On December 19, 2019, PPMD had the privilege of hosting a conversation with Duchenne experts on the importance of optimal care in Duchenne, how care impacts every aspect of our mission to end Duchenne and our…

Learn More

December 20, 2019

Winter Safety & Bone Health

With the official start of winter quickly approaching and the icy weather already here, we want to remind your family about the importance of safety, and also what to do if and when accidents happen….

Learn More